Veracyte Inc (VCYT) Q3 2026 Earnings Call Highlights: Revenue Climbs 15% as Afirma Shines
Veracyte Inc (VCYT) reported Q3 2026 revenue growth of 15%, driven by Afirma. Decipher prostate volume missed expectations by ~1,000 tests, leading to a revised 2027 volume growth outlook of 12,000-15,000 tests. 2027 revenue growth is guided to mid-single digits (~5%), with adjusted EBITDA margin expected to decline to ~22% due to increased commercial investment and expense timing.
How this was made
The 30-second read
Why it matters
The lowered guidance and margin outlook could trigger a short‑term price decline, but the company’s plan to increase commercial headcount may provide a longer‑term upside catalyst.
Market read
Guidance downgrade for a niche diagnostics firm; relevant for traders focused on biotech earnings and sector rotation.
What to watch
Potential upside from prior‑period collections and cost‑saving initiatives not fully reflected in the guidance.
Background
Veracyte's Q3 2026 earnings call highlighted missed Decipher test volume targets and a reset of 2027 volume growth expectations.
Ticker impact
Veracyte guided 2027 revenue growth to mid‑single digits (~5%) and EBITDA margin down to ~22%, down from 27.2% in Q3 2026.
likely downside as investors price in slower growth and lower profitability.
Revenue growth guidance falls short of prior expectations and margin guidance declines, which historically trigger sell pressure.
Market effects
Urology diagnostics sector may see broader valuation adjustments as growth outlook tightens.
U.S. biotech and diagnostics stocks could face modest pullback.
Limited to companies with similar prostate/urinary cancer test portfolios.
Counterpoint
If Veracyte can successfully expand its urology sales force and capture share from digital pathology competitors, the guidance may be overly conservative.
Key entities
- ExecutiveMarc Stapley
CEO of Veracyte, provided commentary on growth dynamics.
- ExecutiveRebecca Chambers
CFO of Veracyte, detailed financial guidance.
